Henbane Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 0.90 M
as on 27-06-2024
- Paid Up Capital ₹ 0.90 M
as on 27-06-2024
- Company Age 22 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.10 M
as on 27-06-2024
- Revenue %
(FY 2021)
- Profit 42.88%
(FY 2021)
- Ebitda 99.83%
(FY 2021)
- Net Worth -0.98%
(FY 2021)
- Total Assets -10.25%
(FY 2021)
About Henbane Pharma (India)
The Company is engaged in the Metals And Minerals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.90 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹7.10 M.
Nalini Batra and Pranav Batra serve as directors at the Company.
- CIN/LLPIN
U24234MH2002PTC136196
- Company No.
136196
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Henbane Pharma (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nalini Batra  | Director | 13-Jun-2002 | Current |
| Pranav Batra | Director | 18-Nov-2013 | Current |
Financial Performance and Corporate Structure Insights of Henbane Pharma (India).
Henbane Pharma (India) Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 42.88% increase in profit. The company's net worth dipped by a decrease of 0.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Henbane Pharma (India)?
In 2021, Henbane Pharma (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bioforce Medicines Private LimitedActive 34 years 3 monthsNalini Batra and Pranav Batra are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bombay Mercantile Co-Operative Bank Limited Creation Date: 19 Aug 2014 | ₹1.80 M | Open |
Bombay Mercantile Co-Operative Bank Limited Creation Date: 07 Aug 2013 | ₹0.30 M | Open |
Bombay Mercantile Co-Operative Bank Ltd. Creation Date: 16 Apr 2013 | ₹5.00 M | Open |
How Many Employees Work at Henbane Pharma (India)?
Unlock and access historical data on people associated with Henbane Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Henbane Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Henbane Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
